Wikipedia -WSS

Wikipedia

author：focus 2025-09-06 01:52:30 - browse：8

Chief executive officer of Sanofi Paul Hudson, wearing glasses, speaks into a mic — pharma coverage from STAT — Sanofi CEO Paul Hudson Carolyn Kaster/AP

LONDON — Sanofi CEO Paul Hudson on Wednesday defended his company’s recent moves to abandon future profit guidance and up its investment in its own research programs, arguing that the dramatically negative market response didn’t reflect the potential rewards that could stem from the plan.

“Would I have liked the stock market reaction to be more generous? Of course,” Hudson said at a Financial Times event in London. “But this is a long-term game, and if you’re trying to deliver long-term value, you try not to make too many short-term decisions.”

Sanofi unveiled its R&D plans late last month as it announced its third-quarter performance and said that it was spinning out its consumer health division. As the company said it was going to spend more money on research, it also withdrew earnings outlooks for 2025. Company executives have argued that this was the moment — when Sanofi has a strong pipeline and isn’t facing patent expirations for years — to increase its R&D resources, even at the expense of short-term profits.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Warren pushes Witty on UnitedHealth's control over physicians

hotspot

WSS

AltruBio raises $225 million to develop ulcerative colitis drug

IVF, abortion rights issues kick off Biden’s State of the Union

Class action alleges UnitedHealth concealed DOJ probe

Sen. Paul opposes bill to ban Chinese biotechs

Welsh Carson private equity firm escapes from FTC antitrust case

Lawmakers grill UnitedHealth CEO on Change cyberattack

entertainment

Wikipedia

explore

Tori Bowie and the unacceptable rates of Black maternal death

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Apple is now the first public company to be valued at $3 trillion

Amylyx ALS drug failure raises questions and concerns

How one medical school became remarkably diverse

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

Walensky prepares to leave CDC — and Congress — behind

GSK’s asthma push continues as drug succeeds in Phase 3 trials

The cancer drug shortage isn’t new — and neither are the solutions

Novo Nordisk obesity pill bests Wegovy in early trial

Wikipedia

BIO to announce reorganization, senior leaders expected to depart

Novo Nordisk obesity pill bests Wegovy in early trial

Sen. Paul opposes bill to ban Chinese biotechs

First medicine developed to treat MASH expected to be approved soon

The effects of a landmark ruling on DNA ownership are becoming clearer

The creative science of coining drug names

entertainment

hotspot

leisure time

focus